Technical Development Agreement
Project Name: Preclinical Pharmacodynamic Research on Endostar’s New Indications
Party A: Jiangsu Simcere Pharmaceutical R&D Co., Ltd.
Party B: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
Contract No.: 06310434000
Date: November 2, 2006
Place of Signature: Shanghai
Parties hereto hereby sign this Agreement to deal with relevant matters concerning the preclinical pharmacodynamic research
on Endostar’s new indication:
1. Technologies and Relevant Requirements
1.1 Party B shall complete the preclinical pharmacodynamic research on Endostar’s new indications in accordance with
declaration requirements of Class I New Drug, and shall provide related data generated from the research to Party A, and shall
assure that these data may be directly used to carry out IND applications for Endostar’s new indication, such as colon
carcinoma, liver cancer, gastric cancer and melanoma, to SFDA.
The specific research shall include:
1.1.1 Anti-tumour experiments in vivo:
Endostar’s experimental therapy of 8 categories of human cancer xenograft models, including human colon carcinoma HCT-116
model, human gastric cancer HT-29 model, human liver cancer Bel-7402 model, human liver cancer SMMC-7721 model, human
gastric cancer SGC-7901 model, human gastric cancer MKN-28 model, human melanoma A375 model and human melanoma
A2058 model, and each model shall go through 2 experiments. Party B shall complete relevant experiments one by one according
to tissue sources of tumors and provide experimental data and reports complying with relevant requirements of SFDA to Party
1.1.2 The design and finalization of relevant experimental schemes concerning above-mentioned experiments.
1.2 Party B shall complete above-mentioned research within fourteen months as from the date when parties hereto sign this
Agreement (from November 10 th , 2006 to January 1 st , 2008), and shall provide all related information, including experimental